I
ImpriMed
Provides cutting-edge personalized medicine easily accessible for pets with blood cancer diseases
About ImpriMed
ImpriMed is a veterinary biotechnology company that has developed a platform to assist in the treatment of cancer in dogs. The company uses artificial intelligence and functional precision medicine to predict how a specific patient will respond to different cancer therapies. The service analyzes live cancer cells from a patient's tumor, creating a personalized profile to identify the most effective treatment options.
The primary clients are veterinary oncologists who use ImpriMed's services to make data-driven decisions for their patients. The company operates in the veterinary oncology market, a growing sector within the broader animal health industry. The business model is based on providing a specialized diagnostic and predictive service. Veterinarians collect samples from their canine patients and send them to ImpriMed's laboratories. The company then performs its analysis and delivers a report through a dedicated online portal, for which it charges a fee.
This approach allows for a more tailored and potentially more effective cancer treatment, moving away from a one-size-fits-all methodology. By providing predictions on drug efficacy, ImpriMed aims to improve patient outcomes and help manage the cost and emotional burden of cancer treatment for pet owners.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Mountain View, United States
- Employees
- 46
- Open positions
- 3
- Dealroom signal
- 76.8/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Precision Medicine, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2023 | $25M | $101M | SK Telecom · SBVA · Mayo Clinic · Murex Partners | ↗ |
| SEEDEquity / VC | Aug 2022 | — | — | Mayo Clinic Platform | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for ImpriMed is 50K monthly website visits, up 16.3% over the last three months. ImpriMed's team declined 2.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed10 investors entered at this stage
Plug and Play
Pear Ventures
Bass Investment
Draper Associates- IVIronfire Ventures
Nextrans Korea
Draper Dragon- BVBlue Bear Ventures
Sazze Partners
Mayo Clinic Platform
Series A12 investors entered at this stage
TransLink Capital
HG Initiative
BonAngels
ES Investor
FuturePlay- MPMurex Partners
SBVA
SK Telecom
Mayo Clinic
Ignite Innovation
SAMYANG CHEMICAL GROUP- BYByucksan
Other known investors4 additional known investors
Jeffrey Lee
SEMA Translink Investment
StartX
Transitions First
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ImpriMed on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ImpriMed’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.